Adelis Equity Partners Fund II (“Adelis”) has divested its majority stake in Europa Biosite, a specialist distributor of Life Science research reagents to EQT Healthcare Growth
Following the acquisition by Adelis in 2021, Europa Biosite has executed on a successful international buy and build strategy acquiring 5 companies in 4 years. By doing so the Company has established a position as the leading specialist distributor in its field – offering innovative products to thousands of Life Science researchers across the continent. In parallel, significant investments have been made into digital tools and marketing that enable a differentiated supplier value proposition and fuel new supplier acquisition and organic growth.
“We are very proud of the part we have played in building a unique European business that supports life science researchers in reaching their goals – ultimately helping to understand and cure disease. On behalf of Adelis, we would like to thank management and all employees, as well as our minority partners and board colleagues for their strong efforts these past years” say Lene Stern and Rasmus Molander. Sune Schmølker, CEO of Europa Biosite says: “We are uniquely positioned to take part in the continued growth of the Life Science reagent market after the significant investments made into building the Group. I am very grateful for the support we have received from Adelis and the board of directors over these past years. I am looking forward to working with the new owners to continue the development of our business”.
The parties have agreed not to disclose the purchase price. The transaction is subject to customary clearance from competition authorities.
Adelis was advised by Houlihan Lokey and White & Case on the transaction.
For further information:
Lucia Morris, Adelis Equity Partners, +46 76 103 12 92, lucia.morris@adelisequity.com
Sune Schmølker, Europa Biosite, sune.schmolker@europabiosite.com
About Europa Biosite
Europa Biosite is a specialist distributor of Life Science research reagents. Carrying a portfolio of over 10 million SKUs, it supports thousands of researchers across Europe and North America in reaching their research objectives. The company has 180 employees covering 17 countries, the majority of whom are scientifically trained and therefore able to provide expert technical support to customers. Under Adelis’ ownership the company has completed 5 acquisitions – creating a truly pan-European commercial footprint and adding further innovative products to the portfolio. For further information, please visit www.europabiosite.com.
About Adelis Equity Partners
Adelis is a growth partner for well-positioned companies in the Nordics and DACH region. Adelis partners with management and/or owners to build businesses in growth segments and with strong market positions. Since raising its first fund in 2013, Adelis has been one of the most active investors in the Nordic middle-market, making 47 platform investments and more than 270 add-on acquisitions. Adelis today manages approximately €4.5 billion in capital. For more information, please visit www.adelisequity.com.
